Revadix
PrivateLast Round
Seed
Apr 11, 2025
Company Overview
Revadix is a biotechnology company developing small molecule therapies targeting the EPAC-1 protein to treat atrial fibrillation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revadix Comparables
Compare Revadix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acesion Pharma | 80% | |
| Thryv Therapeutics | 77% | |
| Sanofi | 69% | |
Revadix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Apr 11, 2025 |
Key People
Founding team and executive leadership
Revadix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NLC Health Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 11, 2025
Seed round led by NLC Health Ventures.
Revadix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Revadix's valuation, stock price, and market status.